Compare Marvell Technology Inc (MRVL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Marvell Technology Inc trades at $211.23 (market cap $171.11B), while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: Marvell Technology Inc pays a 0.12% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Marvell Technology Inc nearer its low. Which is the better fit depends on your goals.
| MRVL | XBI | |
|---|---|---|
Market Cap | $171.11B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $316.43 | $164.28 |
52-Week Low | $62.31 | $85.16 |
Enterprise Value | $172.55B | — |
Dividend Yield | 0.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $207.96, up 10.22% on the day, reflecting strong momentum amid AI-driven chip stock enthusiasm. The stock shows bearish technical signals but benefits from consistent earnings beats and robust analyst support with an 82% buy rating. Recent news highlights its 251% surge in H1 2026 and strategic positioning in AI infrastructure, though volatility persists due to sector-wide capex concerns. Fundamentals reveal high valuation multiples (P/E 66.99) against negative net income, offset by solid gross margins (51.5%) and projected revenue growth to $8.7B in 2026.
Outlook: MRVL offers growth exposure to AI networking and custom silicon, with a consensus price target of $275.68 implying 32% upside. Risks include execution challenges in scaling profitability, debt levels ($3.93B long-term), and sensitivity to AI spending cycles. The stock's premium valuation demands flawless execution to justify current levels amid competitive pressures.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
